Vaxxinity

Covid-19 booster candidate UB-612 has achieved its immunogenicity endpoints in a head-to-head trial against three vaccine platforms: mRNA (Pfizer-BioNTech’s BNT162b2), adenovirus vector (AstraZeneca’s ChAdOx1-S), and inactivated virus (Sinopharm’s BIBP).  The results show UB-612 elicits superior neutralising antibody titers and seroconversion rates against both Wuhan and Omicron BA.5 variants compared to adenovirus vector (ChAdOx1-S) and inactivated […]

Global Phase III topline data is expected later this year for a new class of Covid-19 booster vaccine. Vaxxinity has completed enrollment for the trial, co-sponsored by the Coalition for Epidemic Preparedness Innovations (CEPI). Its UB-612 will be evaluated as a heterologous booster vaccine to mRNA, adeno-vectored, and inactivated primary series vaccinations.  “Completing enrollment in a […]